Over the past two years, 17 states have passed laws legalizing CBD so that patients can obtain the drug without fear of prosecution from local authorities. For intractable childhood epilepsies—the sorts of seizure disorders that for centuries have ruined lives and shattered families, the ones even specialists like Hernandez dread—CBD could be a miracle cure.
As the demand for CBD products has increased, some states have started to take action. Over the past two years, 17 states have passed “CBD-only” laws, assuring parents who purchase CBD oil to treat their sick children that they won’t face arrest or prosecution from state law enforcement for possessing what the federal government still considers a Schedule I narcotic.
Though use of marijuana among Washington state youth has remained relatively stable over the last several years (see Healthy Youth Survey), youth perception of harm from use of marijuana has been steadily decreasing (meaning: fewer adolescents believe marijuana use is harmful). Marijuana is the second most-commonly used substance among 12th graders (alcohol is the first), with 27% of high school seniors reporting current (past 30-day) use.
Last year, the National Academies of Sciences, Engineering and Medicine released a nearly 500-page report on the health effects of cannabis and cannabinoids. A committee of 16 experts from a variety of scientific and medical fields analyzed the available evidence — more than 10,000 scientific abstracts in all. Because so few studies examine the effects of CBD on its own, the panel did not issue any findings about CBD specifically, but it did reach some conclusions about cannabis and cannabinoids more generally. The researchers determined that there is “conclusive or substantial evidence” supporting the use of cannabis or cannabinoids for chronic pain in adults, multiple sclerosis-related spasticity (a kind of stiffness and muscle spasms), and chemotherapy-induced nausea and vomiting. The committee also found “moderate” evidence that cannabis or cannabinoids can reduce sleep disturbances in people with obstructive sleep apnea, fibromyalgia, chronic pain and multiple sclerosis, as well as “limited” evidence that these substances can improve symptoms of Tourette’s syndrome, increase appetite and stem weight loss in people with HIV/AIDs, and improve symptoms of PTSD and anxiety.
The Department has policies and procedures in place for the commonwealth's hemp research program, which can be found in the 2019 Pilot Program Parameters. Researchers from institutions of higher education or growers who would like to be considered for participation in the 2019 program must submit a 2019 PDA Industrial Hemp Research Pilot Program Permit Application prior to the application deadline of December 17, 2018. Researchers who participated in the 2018 Pilot Program may submit a Permit Renewal form by December 17, 2018 to continue their projects in the 2019 growing season.